Everstring

Belkins
EverString’s AI SaaS solution is designed for B2B sales and marketing professionals to drive pipeline growth, help close new customers, expand into new markets, prioritize accounts, and provide actionable insights – all without the need for an administrator. EverString is backed by leading investors including Lightspeed Venture Partners, Sequoia Capital, IDG Ventures and Lakestar.

C-Suite On Deck

Matt Amundson, VP of Marketing at EverString has over 10 years of sales and marketing experience. Matt has held roles in Demand Generation and Sales Development at TIBCO, Marketo, FGXI and Red Bull. His primary focus has been on creating processes that generate a consistent, pipeli...

Events

Related News

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

news image

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More

CELL AND GENE THERAPY

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

news image

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More

MEDICAL

NOVALIS BIOTECH ANNOUNCES THE CLOSING OF A €25 MILLION BIOTECH ACCELERATION FUND

Novalis Biotech | July 01, 2021

news image

Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs). The Biotech Acceleration Fund will continue ...

Read More

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

news image

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More
news image

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More
news image

CELL AND GENE THERAPY

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More
news image

MEDICAL

NOVALIS BIOTECH ANNOUNCES THE CLOSING OF A €25 MILLION BIOTECH ACCELERATION FUND

Novalis Biotech | July 01, 2021

Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs). The Biotech Acceleration Fund will continue ...

Read More
news image

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More

Resources

Events

C-Suite On Deck

Matt Amundson, VP of Marketing at EverString has over 10 years of sales and marketing experience. Matt has held roles in Demand Generation and Sales Development at TIBCO, Marketo, FGXI and Red Bull. His primary focus has been on creating processes that generate a consistent, pipeli...